Literature DB >> 29317292

Effects and management of denosumab discontinuation.

Roland Chapurlat1.   

Abstract

Entities:  

Keywords:  Denosumab; Drug holiday; Fracture; Osteoporosis

Mesh：

Substances：

Year:  2018        PMID： 29317292     DOI： 10.1016/j.jbspin.2017.12.013

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  4 in total

Review 1.  The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.

Authors:  Núria Guañabens; María Jesús Moro-Álvarez; Enrique Casado; Josep Blanch-Rubió; Carlos Gómez-Alonso; Guillermo Martínez Díaz-Guerra; Javier Del Pino-Montes; Carmen Valero Díaz de Lamadrid; Pilar Peris; Manuel Muñoz-Torres
Journal:  Endocrine       Date:  2019-04-08       Impact factor: 3.633

Review 2.  Stopping Denosumab.

Authors:  Olivier Lamy; Delphine Stoll; Bérengère Aubry-Rozier; Elena Gonzalez Rodriguez
Journal:  Curr Osteoporos Rep       Date:  2019-02       Impact factor: 5.096

3.  Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.

Authors:  D M Borek; R C Smith; C N Gruber; B L Gruber
Journal:  Osteoporos Int       Date:  2019-04-22       Impact factor: 4.507

4.  Identification of potential specific biomarkers and key signaling pathways between osteogenic and adipogenic differentiation of hBMSCs for osteoporosis therapy.

Authors:  Jianjun Wu; Peian Cai; Zhenhui Lu; Zhi Zhang; Xixi He; Bikang Zhu; Li Zheng; Jinmin Zhao
Journal:  J Orthop Surg Res       Date:  2020-09-23       Impact factor: 2.359
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.